Hepatocellular carcinoma is the most common type of liver cancer arising from malignant hepatocytes. It is one of the leading causes of death globally. In 2012, HCC was the fifth most common cancer in men and ninth in women with 554,000 and 228,000 cases, respectively, according to the World Health Organization. 
INTRODUCTION
sorafenib, a protein kinase inhibitor that inhibits tumor cell proliferation and angiogenesis.
HepATOCellUlAR CARCINOMA IN MAlAYSIA
Liver cancer is the eighth most common cause of cancer for both gender and fifth most common cause of cancer for males in Malaysia. The annual mortality rate per 100,000 people from liver cancer globally is 11.4% and in Southeast Asia is 12.1%. In Malaysia, it is 6.1% in the year 2013, which showed an increase by 42.8% since 1990, an average of 1.9% a year. 7 Liver cancer is a cause of premature death in Malaysia: The trend from 1990 to 2010 was observed upward. In the year 1990, the ranking of liver cancer as a cause of YLLs was 26, which became 22 in the year 2010. 8 Since 1990, the annual YLLs from liver cancer have increased by 31.5%. Liver cancer disease burden in Malaysians measured by the YLLs per 100,000 people peaks at the age of 70 to 74 years for men and 75 to 79 years for women. It may affect boys as young as 10 to 14 years. 7 There are generally scarce data describing the clinical management of patients with HCC in Malaysia within clinical practice. A descriptive cross-sectional analysis of a hospital-based case series on consecutive HCC patients who presented in 2013 at University Malaya Medical Centre (UMMC) was conducted. The UMMC is one of the teaching hospital and tertiary care referral centers for liver diseases in Malaysia.
There were 115 consecutive HCC patients presented at the hospital in 2013. The mean age (± standard error of mean) of patients at diagnosis with HCC is 61.14 (± 1.11) years, with 80% of patients being male (n = 92). Onethird of the 115 patients were aged 61 to 70 years (n = 40, 34.8%). The majority of the patients are Chinese (n = 69, 60%), followed by Malay (n = 33, 28.7%) and Indian (n = 13, 11.3%). The most common etiology for HCC was HBV infection, which accounted for 51.3% of the patients, while 9.6% of patients had chronic HCV infection, which was comparable to a previous study. 9 Patients were stratified into stages A, B C, and D based on the Barcelona Clinic Liver Cancer staging classification according to results of first diagnostic investigations comprising mainly five-phase computed tomography scan. However, due to variations in the availability of patients' information from the hospital medical records, information on HCC stage at first presentation to UMMC was only available for 89 of the 115 patients.
At initial presentation to the hospital, 36/89 patients presented with stage D HCC. Out of 89 patients 20, 18, and 15 patients were diagnosed with stages B, C, and A respectively. All the 89 patients were further categorized according to the Child-Pugh score of cirrhosis. Of the 15 HCC patients who were in stage A during initial presentation, 13 of them had Child-Pugh A, while another 2 patients had Child-Pugh B score. Half of the patients (n = 10/20) in stage B HCC had Child-Pugh A score and another half (n = 10/20) had Child-Pugh B score of cirrhosis. In stage C, 5/18 and 13/18 HCC patients had Child-Pugh A and B score respectively. All patients (n = 36) in stage D had Child-Pugh C score at initial presentation to UMMC (Table 1) .
Various health care resources were utilized in the clinical management of HCC patients. Resource use was categorized based on the health care setting of the treatment received, which comprised clinic visits, admission, RFA procedure, TACE procedure, and medical managements of liver cirrhosis related to HCC. The estimated direct medical costs for HCC were calculated from the healthcare provider's perspective, using relevant unit costs as published in a previous study conducted in UMMC. 10 The costs were inflation-adjusted according to a rate of 2.2%, to reflect the costs of HCC management in 2013. The estimated annual cost of managing all HCC patients (n = 115) at UMMC in 2013 is USD 886,995. This analysis was based on retrospective data extracted from medical records. While there could be data gaps that may lead to incomplete description of the clinical treatment received, this analysis presents the best current information on the estimated costs of HCC in Malaysia. Future work should focus on refining these estimates to help inform future strategies for HCC in Malaysia.
CHANGING TReNDS OF HCC IN MAlAYSIA
Hepatitis B virus remained the major cause of HCC in Malaysia. Availability of effective HBV vaccine and nationwide vaccination programs, more affordable drugs, and a comprehensive national strategy will help to control and eliminate HBV in the near future. The increase in the number of HCC cases due to HBV is the reflection of already significant disease burden. 11 Hepatitis C virus remains a concern for Malaysia as many infected persons are unaware of their infected A more recent cross-sectional study of all HCC (115) cases in 2015 in UMMC (data unpublished) also showed that predominant etiology was HBV (51.3%), cryptogenic (35.7%), HCV (9.6%), and alcohol (3.5%).
Another study by Norsa'adah and NurhazaliniZayani 11 on 210 HCC patients from 1987 to 2008 showed age prevalence of ≥60 is maximum (38.1%). Hepatitis B virus (57.6%) remained the major cause of HCC followed by cryptogenic (28.1%) as second most common cause. At the time of diagnosis, most of the patients were symptomatic and presented at an advanced stage of HCC.
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All these above studies show that after HBV, cryptogenic/NAFLD/NASH is the predominant cause of HCC, which can be correlated with the increasing incidence of diabetes and obesity in Malaysia. The obesity statistics in the Asia-Pacific region showed that Malaysia is the most obese Asian country. 13 
CONClUSION
Hepatocellular carcinoma has long been a major public health problem with a very high mortality, especially in Asia. In Asia-Pacific region, HBV remains the major cause of HCC except Japan. A changing etiology of HCC in Asia and in Malaysia is largely due to the rising epidemic of obesity and diabetes being the underlying cause of NAFLD, especially its more aggressive form, NASH a major contributor to HCC. Prevention and control of viral hepatitis and curbing the growing epidemic of obesity and diabetes must be seen as a key part of HCC prevention. An optimal surveillance strategy also is crucial to detect early HCC and a proper insight on socioeconomic impact of HCC burden may help people to become aware of the situation.
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